Technology News


Technology News

Luncheon Symposium CIT 2012

2014-07-06 19:23:40

China hosted its Luncheon Symposium on the 16th March in Beijing. The Lunchen Symposium is entitled ‘superior performance by early endothelial healing.’ It was chaired by Prof. Yongjian Wu from Fuwai Hospital CAMS & PUMC, Prof. Yong Huo from Peking University First Hospital and Dr. Renu Virmani from CVpath in U.S. During the symposium, Prof. Bo Yu from the 2nd affiliated hospital of Harbin Medical University shared the latest results (3 month) comparing BuMA™ with XIENCE V using OCT (optical coherence tomography). The objective of this analysis is to observe any difference in two kinds of stent by using OCT method. Furthermore, In this study, it is designed to implant BuMA™ and XIENCE V overlapped in the same lesion, same vessel of the same patient to optimally reduce blood vessel variances. In total, 20 are enrolled in this study evenly divided in each group. Angiography and OCT will be taken before and 3, 6 and 12 months after implantation. The primary endpoint is endothelial coverage at 3 months. Secondary endpoint includes endothelial coverage at 12 months, clinical events and clinical follow-up up to 2 years.

Preliminary results for 3 month follow-up indicated that BuMA™ has reached 95% strut coverage where XIENCE V has reached 94.7%. However, these results were not significant. Prof. Yong Huo has shown his appreciation on the unique study design. He discussed about the originality of the study design where BuMA™ is the first domestic brand with an international head to head comparison study. The 3 month results may also lead to a shorter DAPT treatment which encourages for further study.

Dr. Renu Virmani from CVPath presented her study on young adult New Zealand rabbits comparing BMS, Cypher and BuMA™ observing the process of endothelialization. In this study, BuMA™ showed superior results in endothelial cell maturation compared to BMS. Dr. Renu Virmani also discussed that the coating of BuMA™ can effectively enhance mechanical resistance and guarantees stable drug coating. Further, it also significantly promotes endothelialization and neointimal coverage. Finally, Prof. Changjian Hong and Prof. Shangyu Wen shared a successfully completed application of BuMA™ within a tortuous calcified stenosis and demonstrated excellent passing performance.

Online message